Katsuyuki Sakanaka

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications

Squamous cell carcinoma antigen and carcinoembryonic antigen monitoring during post-definitive chemoradiotherapy surveillance for esophageal squamous cell carcinoma: JCOG2106A.

Squamous cell carcinoma antigen and carcinoembryonic antigen monitoring during post-definitive chemoradiotherapy surveillance for esophageal squamous cell carcinoma: JCOG2106A.

Journal: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
Published: March 29, 2026

Oligometastatic esophageal squamous cell carcinoma: a systematic review of current definitions and meta-analysis of local therapy outcomes.

Oligometastatic esophageal squamous cell carcinoma: a systematic review of current definitions and meta-analysis of local therapy outcomes.

Journal: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
Published: March 12, 2026

Cost-effectiveness analysis of chemoradiotherapy compared to surgery in patients with stage I esophageal squamous cell carcinoma in Japan.

Cost-effectiveness analysis of chemoradiotherapy compared to surgery in patients with stage I esophageal squamous cell carcinoma in Japan.

Journal: International journal of clinical oncology
Published: February 19, 2026

Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU).

Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU).

Journal: BMC cancer
Published: September 29, 2025

Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial.

Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial.

Journal: EClinicalMedicine
Published: August 27, 2025

Clinical Implications of Nutritional Intake in Patients With Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy and Neoadjuvant Chemotherapy.

Clinical Implications of Nutritional Intake in Patients With Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy and Neoadjuvant Chemotherapy.

Journal: Cancer medicine
Published: August 13, 2025

Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.

Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.

Journal: Esophagus : official journal of the Japan Esophageal Society
Published: June 30, 2025

Treatment resistance factors associated with Talaporfin sodium photodynamic therapy for local control after chemoradiotherapy for esophageal cancer.

Treatment resistance factors associated with Talaporfin sodium photodynamic therapy for local control after chemoradiotherapy for esophageal cancer.

Journal: Esophagus : official journal of the Japan Esophageal Society
Published: April 30, 2025

Improvement in Quality of Life and Dysphagia After Palliative External Beam Radiotherapy for Malignant Esophageal Stenosis of Esophageal Cancer.

Improvement in Quality of Life and Dysphagia After Palliative External Beam Radiotherapy for Malignant Esophageal Stenosis of Esophageal Cancer.

Journal: JCO oncology practice
Published: March 13, 2025

ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?

ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?

Journal: Annals of surgical oncology
Published: September 19, 2024

Safety and Efficacy of Conversion Therapy After Systemic Chemotherapy in Advanced Esophageal Cancer with Distant Metastases: A Multicenter Retrospective Observational Study.

Safety and Efficacy of Conversion Therapy After Systemic Chemotherapy in Advanced Esophageal Cancer with Distant Metastases: A Multicenter Retrospective Observational Study.

Journal: Annals of surgical oncology
Published: May 20, 2024

Effect of replanning boost radiotherapy plan in locally advanced unresectable middle to lower thoracic esophageal cancer.

Effect of replanning boost radiotherapy plan in locally advanced unresectable middle to lower thoracic esophageal cancer.

Journal: Scientific reports
Published: April 23, 2024
Showing 1-12 of 55

Last Updated: 09/26/2026